Odimma Therapeutics Strengthens Its Platform Through Strategic Partnership with Touchlight
———————
Enabling the Next Generation of Personalized Cancer Immunotherapy with Synthetic DNA Manufacturing.
Odimma Therapeutics has established a strategic partnership with Touchlight, the UK biotechnology company pioneering enzymatic DNA production, to support the clinical development of its personalized cancer immunotherapy platform.
The collaboration provides Odimma with access to Touchlight’s proprietary doggybone DNA (dbDNA™) technology, a next-generation synthetic DNA manufacturing platform specifically designed for advanced genetic medicines. The agreement supports the production of clinical-grade DNA for Odimma’s neoantigen-based immunotherapy candidate, reinforcing the company’s ambition to deliver highly personalized cancer treatments with unprecedented speed and flexibility.
Accelerating Personalized Oncology
Personalized cancer immunotherapy requires manufacturing technologies capable of producing patient-specific therapeutic material within exceptionally short timelines.
Traditional plasmid DNA manufacturing often relies on lengthy bacterial production processes and complex supply chains that can delay treatment development.
Touchlight’s enzymatic dbDNA™ platform addresses these limitations by enabling DNA production in as little as five days, providing the speed and scalability required for truly individualized immunotherapy approaches.
This manufacturing capability represents an important component of Odimma’s platform strategy, supporting rapid development while maintaining the quality standards required for clinical application.
A Platform Designed Around the Patient
Odimma’s technology is based on the identification of tumor-specific neoantigens, allowing each therapeutic candidate to be tailored to the unique molecular signature of an individual patient’s cancer.
By combining AI-assisted neoantigen selection, synthetic DNA technologies and advanced immune activation strategies, Odimma is developing a scalable platform intended to expand the potential of personalized immunotherapy across multiple oncology indications.
The partnership with Touchlight provides a critical industrial foundation for this vision, ensuring that manufacturing timelines remain compatible with personalized treatment approaches.
Leadership Perspective
Commenting on the collaboration, Jean-Marc Limacher, MD, Chairman and Co-Founder of Odimma Therapeutics, stated:
“Our agreement with Touchlight represents an important milestone for Odimma’s clinical development. Their synthetic DNA technology combines outstanding characteristics for clinical use with manufacturing timelines that are uniquely suited to personalized immunotherapy in oncology.”
Karen Fallen, Chief Executive Officer of Touchlight, added that enzymatic DNA manufacturing is helping overcome long-standing industry bottlenecks and enabling innovative immunotherapy programs to reach patients more rapidly.
Building the Future of Precision Oncology
The collaboration illustrates Odimma’s strategy of assembling world-class technology partners to create a next-generation immunotherapy platform that is both scientifically differentiated and industrially scalable.
As personalized oncology continues to evolve, partnerships integrating advanced genomic analysis, AI-driven target selection and rapid synthetic DNA manufacturing will play an increasingly important role in delivering individualized therapies to patients with difficult-to-treat cancers.
For Odimma Therapeutics, the collaboration with Touchlight represents another step toward transforming precision immunotherapy from scientific promise into clinical reality.
